“The next new $1trn stock will be…”

There are a very select few stocks that have seen their market cap exceed $1trn. And those that bought shares before that milestone will be very happy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since The Motley Fool’s mission statement is to make the world smarter, happier and richer, we asked some of our freelance writers which US stocks they think might be next to crack the $1trn threshold — potentially making shareholders very happy indeed!

Berkshire Hathaway

What it does: Warren Buffett’s diversified holding company uses an insurance float model to invest in dozens of businesses.

By Charlie CarmanBerkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) has broken the $700bn market capitalisation barrier, but it’s never reached the trillion-dollar threshold. I think that’s only a matter of time. As I write, the company would need to deliver a 36% share price gain to achieve this landmark.

From 1965 to 2022, Berkshire Class A stock achieved a 19.8% compound annual growth rate. Returns have slowed since the turn of the millennium, but the annual average remains firmly in double digits.

Recent results have been encouraging. In the first quarter, Berkshire posted a $35.5bn profit and accelerated its share repurchases, buying back $4.4bn of its own stock.

A major risk facing the company is the potential loss of investor confidence that could result from its CEO’s looming departure. After all, Buffett is 92.

However, his successor Greg Abel has already taken on many responsibilities, suggesting the handover could be less problematic than some fear.

Charlie Carman owns shares in Berkshire Hathaway. 

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate that operates in sectors including insurance and retail and owns a stock portfolio.

By Christopher Ruane. The famed investor Warren Buffett has built Berkshire Hathaway over the course of decades.

Since taking the company over in 1965, Buffett has achieved a compounded annual gain of 19.8% in its per-share market value.

Some years are markedly better than others. In general, I think the defensive nature of many Berkshire businesses means that it can do well when the wider market stumbles. In 2007, for example, its compounded annual gain was 28.7% while the benchmark S&P 500 only achieved 5.5%.

The economy looks weak again to me, but one big difference is Berkshire’s massive position in Apple. If tech stocks including Apple fall, that could hurt Berkshire’s share price.

But I think the company’s broadly defensive asset base and Buffett’s steady hand on the tiller could help Berkshire ride out the next storm well. Its shares have risen 81% in five years and today the market capitalisation is $736bn.  

Christopher Ruane does not own shares in any of the companies mentioned.

Eli Lilly

What it does: Eli Lilly is a global healthcare company with products spanning oncology, immunology, diabetes and neurology.

By Ben McPoland. I think biopharma giant Eli Lilly (NYSE: LLY) could become the newest $1trn stock. Its market cap of $435bn already makes it one of the largest companies in the world.

The firm has a packed late-stage pipeline of potential blockbusters. One is its Alzheimer’s treatment, donanemab,which has successfully slowed memory and thinking decline in a rigorous phase 3 trial.

A second is Mounjaro, which is a medicine already used by people with type 2 diabetes. It is currently being assessed by US regulators and the NHS as a repositioned treatment for weight loss.

Needless to say, a proven and safe treatment for obesity (which is a global health issue) could be a huge deal for the company. Indeed, some analysts think it could become the biggest selling drug ever. And it could be approved by the end of this year. 

One risk is that this huge potential is already priced into the stock, with its trailing P/E of 72. Any disappointing regulatory news could hit the share price hard.  

Ben McPoland does not own shares in Eli Lilly.

The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

ISA coins
Investing Articles

How much would you need in a Stocks & Shares ISA to target a £2,000 monthly passive income?

How big would a Stocks and Shares ISA have to be to throw off thousands of pounds in passive income…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

£10,000 invested in Diageo shares 4 years ago is now worth…

Harvey Jones has taken an absolute beating from his investment in Diageo shares but is still wrestling with the temptation…

Read more »

Investing Articles

Dividend-paying FTSE shares had a bumper 2025! What should we expect in 2026?

Mark Hartley identifies some of 2025's best dividend-focused FTSE shares and highlights where he thinks income investors should focus in…

Read more »

piggy bank, searching with binoculars
Dividend Shares

How long could it take to double the value of an ISA using dividend shares?

Jon Smith explains that increasing the value of an ISA over time doesn't depend on the amount invested, but rather…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£5,000 invested in Tesco shares 5 years ago is now worth this much…

Tesco share price growth has been just part of the total profit picture, but can our biggest supermarket handle the…

Read more »

Investing Articles

Here’s why I’m bullish on the FTSE 100 for 2026

There's every chance the FTSE 100 will set new record highs next year. In this article, our Foolish author takes…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Growth Shares

UK interest rates fall again! Here’s why the Barclays share price could struggle

Jon Smith explains why the Bank of England's latest move today could spell trouble for the Barclays share price over…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

2 out-of-favour FTSE 250 stocks set for a potential turnaround in 2026

These famous retail stocks from the FTSE 250 index have crashed in 2025. Here's why 2026 might turn out to…

Read more »